$NVAX Let us look at things logically. The mRNA vaccines do not protect as long as it was thought they would. There is a lot of hesitancy about a booster shot, especially among those that had major adverse reactions to their 1st or 2nd shot. This leaves a large unmet need for an Alternative to mRNA In the US and other countries. Europe is in deep trouble, their case counts are increasing dramatically and I suspect most of Europe is on the verge of another lockdown. India is a wildcard. Their infections are decreasing, yet may be severely underreported; especially in the rural areas. Novavax has applied for emergency approval th the regions hardest hit by increasing cases now. Sourced news articles indicate approvals will be forthcoming within weeks, certainly by EOY. If you can afford to do so, add to position, under no circumstances think about selling. GLTA